Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: Sources of variability and predictors of adverse effects in 419 healthy subjects

European Journal of Clinical Pharmacology

Volumn 61, Issue 11, 2005, Pages 821-829

  Funck Brentano, Christian ^a,b,c   Boëlle, Pierre Yves ^b,d   Verstuyft, Céline ^b,c   Bornert, Célia ^b,c   Becquemont, Laurent ^b,c   Poirier, Jean Marie ^b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHOXYMORPHINAN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG METABOLITE; ERGIX; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; DATA BASE; DIZZINESS; DROWSINESS; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; LOGISTIC REGRESSION ANALYSIS; MALE; MULTIVARIATE ANALYSIS; NAUSEA; NORMAL HUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING HABIT; SOMNOLENCE;

ADULT; ANALGESICS, OPIOID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES;

EID: 28344457549     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0051-5     Document Type: Article

References (55)

1. Streetman DS, Bertino JS Jr,Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216
2. Kivisto KT, Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37:40S-48S
3. Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624
4. Kupfer A, Schmid B, Pfaff G (1986) Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 16:421-433
5. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 65:570-575
6. Tennezé L, Verstuyft C, Becquemont L, Poirier JM, Wilkinson GR, Funck-Brentano C (1999) Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. Clin Pharmacol Ther 66:582-588
7. Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP (2002) The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 71:1149-1160
8. Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J et al. (2000) Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10:425-438
9. Chladek J, Zimova G, Martinkova J, Tuma I (1999) Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects. Fundam Clin Pharmacol 13:508-515
10. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R et al. (1998) Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 8:403-410
11. Chou WH, Yan FX, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C et al. (2003) Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 49:542-551
12. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
13. He N, Daniel HI, Hajiloo L, Shockley D (1999) Dextromethorphan O-demethylation polymorphism in an African-American population. Eur J Clin Pharmacol 55:457-459
14. Lamba V, Lamba JK, Dilawari JB, Kohli KK (1998) Genetic polymorphism of CYP2D6 in North Indian subjects. Eur J Clin Pharmacol 54:787-791
15. Funck-Brentano C, Thomas G, Jacqz-Aigrain E, Poirier JM, Simon T, Bereziat G et al. (1992) Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 263:780-786
16. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Gaedigk A et al. (1999) Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics 9:453-462
17. Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, Schwartz JB (1999) In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 66:40-50
18. Min DI, Ku YM, Vichiendilokkul A, Fleckenstein LL (1999) A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. Pharmacotherapy 19:753-759
19. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204
20. Ducharme J, Abdullah S, Wainer IW (1996) Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 678:113-128
21. Jones DR, Gorski JC, Hamman MA, Hall SD (1996) Quantification of dextrometliorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr B Biomed Appl 678:105-111
22. Jones DR, Gorski JC, Haehner BD, O'Mara EM Jr, Hall SD (1996) Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 60:374-384
23. Chou YC, Liao JF, Chang WY, Lin MF, Chen CF (1999) Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res 821:516-519
24. Klein M, Musacchio JM (1992) High-affinity dextromethorphan and (+-3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine binding sites in rat brain. Allosteric effects of ropizine. J Pharmacol Exp Ther 260:990-999
25. Pechnick RN, Poland RE (2004) Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary- adrenal axis. J Pharmacol Exp Ther 309:515-522
26. Steinberg GK, Bell TE, Yenari MA (1996) Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. J Neurosurg 84:860-866
27. Bem JL, Peck R (1992) Dextromethorphan. An overview of safety issues. Drug Saf 7:190-199
28. Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lotsch J (2003) Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 74:303-311
29. Kharasch ED, Hoffer C, Whittington D, Sheffels P (2003) Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 74:543-554
30. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB et al. (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348:1442-1448
31. Mayer P, Hollt V (2001) Allelic and somatic variations in the endogenous opioid system of humans. Pharmacol Ther 91:167-177
32. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L et al. (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95:9608-9613
33. East T, Dye D (1985) Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 338:99-112
34. Verstuyft C, Morin S, Yang J, Loriot MA, Barbu V, Kerb R et al. (2003) Nouvelle méthode rapide et robuste de génotypage du CYP2C9 et MDR1. Ann Biol Clin (Paris) 61:305-309
35. Motulsky HJ, Ransnas LA (1987) Fitting curves to data using nonlinear regression: a practical and nonmathematical review. Faseb J 1:365-374
36. Akaike H (1976) An information criterion (AIC). Math Sci 14:5-7
37. Larrey D, Amouyal G, Tinel M, Letteron P, Berson A, Labbe G et al. (1987) Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol 24:676-679
38. Steiner E, Iselius L, Alvan G, Lindsten J, Sjoqvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38:394-401
39. Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brockmeier D et al. (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyl-transferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209-218
40. Streetman DS, Ellis RE, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R et al. (1999) Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clin Pharmacol Ther 66:535-541
41. Kallio J, Lindberg R, Huupponen R, Iisalo E (1988) Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Br J Clin Pharmacol 26:791-795
42. Siegmund W, Hanke W, Zschiesche M, Franke G, Biebler KE, Wilke A (1990) N-acetylation and debrisoquine type oxidation polymorphism in Caucasians - with reference to age and sex. Int J Clin Pharmacol Ther Toxicol 28:504-509
43. Hägg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169-173
44. McCune JS, Lindley C, Decker JL, Williamson KM, Meadowcroft AM, Graff D et al. (2001) Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol 41:723-731
45. Vincent-Viry M, Fournier B, Galteau MM (2000) Short communication. The effects of drinking and smoking on the CYP2D6 metabolic capacity. Drug Metab Dispos 28:617-619
46. Eap CB, Buclin T, Hustert E, Bleiber G, Golay KP, Aubert AC et al. (2004) Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 60:231-236
47. Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Brentano C (2002) Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther 72:514-523
48. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J et al. (2000) In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68:356-366
49. Vetticaden SJ, Cabana BE, Prasad VK, Purich ED, Jonkman JH, de Zeeuw R et al. (1989) Phenotypic differences in dextromethorphan metabolism. Pharm Res 6:13-19
50. Miners JO, Birkett DJ (1993) The misuse of urinary metabolite excretion data in drug metabolism studies. Pharmacogenetics 3:58-59
51. Weinbroum AA, Rudick V, Paret G, Ben-Abraham R (2000) The role of dextromethorphan in pain control. Can J Anaesth 47:585-596
52. Price LH, Lebel J (2000) Dextromethorphan-induced psychosis. Am J Psychiatry 157:304
53. Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33
54. van Tellingen O (2001) The importance of drug-transporting P-glycoproteins in toxicology. Toxicol Lett 120:31-41
55. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237